Biomx merger CHAC

BiomX, a biotech company developing natural and engineered phages to treat microbiome diseases, announced a merger agreement with Chardan Healthcare Acquisition Corp. The combined company is expected to be listed on the New York Stock Exchange under the name BiomX, and will proceed with developing BiomX’s phage products. This is a big deal for phage biotech as a field, as it means more public visibility and more funding, and importantly, it’s a signal that investors are gaining confidence in phage-based technologies.